drugset / Trial / NCT01516424

Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

NCT01516424

Phase 3 Completed 267 enrolled Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone

Timeline

Start
2012-02
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Blonanserin Small molecule 8 mg
Subject Blonanserin Small molecule 24 mg
Comparator Risperidone Other / unclassified 2 mg
Comparator Risperidone Other / unclassified 6 mg

Indications